On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
Inserm · Economic & Social Sciences, Health Systems & Medical Informatics · +19 more institutions
Abstract
Antiretroviral preexposure prophylaxis has been shown to reduce the risk of human immunodeficiency virus type 1 (HIV-1) infection in some studies, but conflicting results have been reported among studies, probably due to challenges of adherence to a daily regimen.
We conducted a double-blind, randomized trial of antiretroviral therapy for preexposure HIV-1 prophylaxis among men who have unprotected anal sex with men. Participants were randomly assigned to take a combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or placebo before and after sexual activity. All participants received risk-reduction counseling and condoms and were regularly tested for HIV-1 and HIV-2 and other sexually transmitted infections.
Citation impact
- FWCI
- 96.07
- Percentile
- 100%
- References
- 21
Authors
36- JMJean‐Michel MolinaCorresponding
- CCCatherine Capitant
Inserm
- BSBruno Spire
Economic & Social Sciences, Health Systems & Medical Informatics, Inserm
- GPGilles Pialoux
Sorbonne Paris Cité, Sorbonne Université, Université Paris Cité, Inserm, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Délégation Paris 7, Hôpital Tenon
- LCLaurent Cotte
Hôpital de la Croix-Rousse
Topics & keywords
- Medicine
- Regimen
- Pre-exposure prophylaxis
- Human immunodeficiency virus (HIV)
- Secondary prophylaxis
- Infection risk
- Men who have sex with men
- Immunology
- Good health and well-being